Arcutis Biotherapeutics (ARQT) Announces Enrolling the First Child in Phase 2 Trials

Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT) is one of the 10 Best Small-Cap Growth Stocks to Buy According to Analysts. On June 10, Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT) announced enrolling the first child in its Phase 2 clinical trials called INTEGUMENT-INFANT. The trial aims to test the safety and tolerability of an investigational topical treatment, ZORYVE cream 0.05% in infants aged 3 months to less than 24 months with mild to moderate atopic dermatitis.

There are currently very few approved topical or systemic therapies for infants with atopic dermatitis. Atopic dermatitis lifelong chronic condition in children that can impact the entire family by significantly disrupting sleep, increasing the risk of skin infections, and leading to developmental and emotional strain for both the child and caregivers, said Patrick Burnett, MD, PhD, FAAD, chief medical officer at Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT).

A biotechnologist working in a laboratory, examining the effects of a Janus Kinase type 1 inhibitor on plaque psoriasis.

This INTEGUMENT-INFANT trial builds on previous positive results from the MUSE study, which also evaluated roflumilast cream 0.05% in infants with atopic dermatitis. ZORYVE cream contains roflumilast, a highly potent and selective phosphodiesterase-4 inhibitor designed for topical use.

Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT) is a commercial-stage dermatology company focused on developing innovative treatments for immune-mediated skin diseases. It develops targeted topical therapies for major inflammatory skin conditions such as atopic dermatitis and alopecia areata.

While we acknowledge the potential of ARQT as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: The Best and Worst Dow Stocks for the Next 12 Months and 10 Unstoppable Stocks That Could Double Your Money.

Disclosure: None.